Drugs / EYP001a
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04037618 | Jul 2019 | — | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03976687 | Jun 2019 → May 2020 | metabolic dysfunction-associated steatohepatitis | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03469583 | Feb → Jun 2018 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03272009 | Sep 2017 → Jul 2018 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03320616 | Feb → Oct 2017 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03110276 | Aug 2016 → Mar 2017 | — | Enyo Pharma | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04365933 | May 2020 → Jun 2021 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
| Phase 2 | NCT04465916 | May 2020 → Jun 2021 | chronic hepatitis B virus infection | Enyo Pharma | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYP001a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04037618 ↗ |
| Known as | EYP001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03469583 ↗ |
| Action | Activate | “EYP001a is a selective, synthetic FXR agonist” NCT03110276 ↗ |
| Route | Oral | “Administered orally once daily.” NCT03110276 ↗ |